Inovio Pharmaceuticals Faces Class Action Over Delayed Drug Application
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy INO?
Source: Businesswire
- Lawsuit Background: The Law Offices of Howard G. Smith remind investors that April 7, 2026, is the deadline to file a lead plaintiff motion in a class action on behalf of investors who purchased Inovio Pharmaceuticals (NASDAQ: INO) securities between October 10, 2023, and December 26, 2025, highlighting investor concerns over the company's future prospects.
- Financial Impact: On August 8, 2024, Inovio reported its Q2 financial results, revealing a delay in submitting the Biologics License Application (BLA) to mid-2025 due to manufacturing issues, which caused its stock to drop 3.1% to $8.44 per share the following day, indicating market skepticism regarding the company's management capabilities.
- FDA Review Dynamics: On December 29, 2025, Inovio disclosed that the FDA accepted its INO-3107 BLA on a standard review timeline instead of an accelerated one, leading to a 24.45% drop in stock price to $1.73 per share, further exacerbating investor losses and reflecting the company's challenges in regulatory compliance.
- False Statement Allegations: The lawsuit alleges that Inovio failed to disclose manufacturing deficiencies and their impact on the INO-3107 application throughout the class period, leading to investor misconceptions about the company's prospects, which underscores significant shortcomings in the company's transparency and integrity.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INO
Wall Street analysts forecast INO stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 1.670
Low
3.00
Averages
7.33
High
13.00
Current: 1.670
Low
3.00
Averages
7.33
High
13.00
About INO
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Inovio Pharmaceuticals Faces Class Action Over Delayed Drug Application
- Lawsuit Background: The Law Offices of Howard G. Smith remind investors that April 7, 2026, is the deadline to file a lead plaintiff motion in a class action on behalf of investors who purchased Inovio Pharmaceuticals (NASDAQ: INO) securities between October 10, 2023, and December 26, 2025, highlighting investor concerns over the company's future prospects.
- Financial Impact: On August 8, 2024, Inovio reported its Q2 financial results, revealing a delay in submitting the Biologics License Application (BLA) to mid-2025 due to manufacturing issues, which caused its stock to drop 3.1% to $8.44 per share the following day, indicating market skepticism regarding the company's management capabilities.
- FDA Review Dynamics: On December 29, 2025, Inovio disclosed that the FDA accepted its INO-3107 BLA on a standard review timeline instead of an accelerated one, leading to a 24.45% drop in stock price to $1.73 per share, further exacerbating investor losses and reflecting the company's challenges in regulatory compliance.
- False Statement Allegations: The lawsuit alleges that Inovio failed to disclose manufacturing deficiencies and their impact on the INO-3107 application throughout the class period, leading to investor misconceptions about the company's prospects, which underscores significant shortcomings in the company's transparency and integrity.
See More
Inovio Pharmaceuticals Securities Fraud Lawsuit Reminder
- Lawsuit Deadline: The Law Offices of Howard G. Smith remind investors that April 7, 2026, is the deadline to file a lead plaintiff motion for those who purchased Inovio securities between October 10, 2023, and December 26, 2025, highlighting the urgency and significance of the case.
- Financial Impact: On August 8, 2024, Inovio released its Q2 financial results, indicating a delay in submitting the Biologics License Application due to manufacturing issues, which caused the stock price to drop 3.1% to $8.44 per share the following day, directly affecting investor confidence.
- FDA Review Update: On December 29, 2025, Inovio disclosed that the FDA accepted its INO-3107 BLA but on a standard review timeline rather than the anticipated accelerated review, leading to a 24.45% stock price decline to $1.73 per share, further exacerbating investor losses.
- False Statements Allegations: The lawsuit alleges that throughout the class period, Inovio failed to disclose deficiencies in the manufacturing of its CELLECTRA device, resulting in misleading positive statements about the regulatory and commercial prospects of INO-3107, severely misguiding investor judgment.
See More
Inovio Pharmaceuticals Investors Class Action Notice
- Class Action Initiated: The Portnoy Law Firm advises Inovio Pharmaceuticals investors of a class action for those who purchased securities between October 10, 2023, and December 26, 2025, with a deadline of April 7, 2026, to file a lead plaintiff motion to protect their legal rights.
- False Statements Allegations: The lawsuit claims that during the class period, Inovio's management made false and misleading statements, failing to disclose deficiencies in the manufacturing of its CELLECTRA device, which decreased the likelihood of submitting the INO-3107 Biologics License Application (BLA) to the FDA.
- FDA Review Outcome: On December 29, 2025, the FDA accepted Inovio's INO-3107 BLA but indicated that the company did not provide sufficient information to justify eligibility for accelerated approval, leading to overstated regulatory and commercial prospects for the product.
- Significant Stock Drop: Following the FDA announcement, Inovio's stock price fell by $0.56, or 24.45%, closing at $1.73 per share, reflecting a pessimistic market sentiment regarding the company's future, resulting in investor losses.
See More
Inovio Pharmaceuticals Shareholder Class Action Notice
- Class Action Notice: The Gross Law Firm has issued a notice encouraging shareholders who purchased Inovio Pharmaceuticals (NASDAQ: INO) shares between October 10, 2023, and December 26, 2025, to contact them for potential lead plaintiff appointment to partake in recovery.
- Allegations Overview: The complaint alleges that during the class period, Inovio made materially false and misleading statements, failing to disclose deficiencies in the manufacturing of its CELLECTRA device, which overstated the regulatory prospects of its lead product candidate, INO-3107.
- Regulatory Approval Concerns: Due to manufacturing issues, Inovio is unlikely to submit its BLA for INO-3107 to the FDA by the second half of 2024, which could adversely affect the company's future revenue and market performance.
- Shareholder Registration Deadline: Shareholders must register for the class action by April 7, 2026, to avoid losing their claim opportunities, with the Gross Law Firm offering portfolio monitoring services to keep investors updated on the case's progress.
See More
Inovio Pharmaceuticals Shareholder Class Action Notice
- Class Action Notice: The Gross Law Firm has issued a notice to shareholders of Inovio Pharmaceuticals, encouraging those who purchased INO shares between October 10, 2023, and December 26, 2025, to contact the firm regarding potential lead plaintiff appointment for recovery participation.
- Allegations: The complaint alleges that during the class period, Inovio made materially false and misleading statements, failing to disclose deficiencies in the manufacturing of its CELLECTRA device, which may delay the submission of its lead product candidate INO-3107 to the FDA until the second half of 2024.
- Regulatory Uncertainty: Inovio lacked sufficient information to justify INO-3107's eligibility for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects, which could result in significant losses for investors.
- Participation Deadline: The deadline for shareholders to register for the class action is April 7, 2026, and those who do not register may miss the opportunity for claims, thus it is advised to act promptly to protect their rights.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit Notification
- Class Action Initiation: Levi & Korsinsky LLP has notified investors in Inovio Pharmaceuticals of a class action lawsuit due to alleged securities fraud, covering the period from October 10, 2023, to December 26, 2025, aimed at recovering losses for affected investors.
- Allegation Details: The complaint alleges that defendants concealed deficiencies in the manufacturing of Inovio's CELLECTRA device, which may delay the submission of its lead product candidate, INO-3107, to the FDA until the second half of 2024, and lacked sufficient information to justify its eligibility for accelerated approval, impacting its market prospects.
- Investor Rights: Affected investors have until April 7, 2026, to request to be appointed as lead plaintiff, with participation in any recovery requiring no out-of-pocket costs, ensuring investor rights are protected.
- Legal Team Strength: Levi & Korsinsky boasts 20 years of experience in securities litigation, having secured hundreds of millions for shareholders, and has been ranked among the top securities litigation firms in the U.S. for seven consecutive years, showcasing its expertise in complex securities cases.
See More
Inovio Pharmaceuticals Faces Class Action Over Delayed Drug Application
- Lawsuit Background: The Law Offices of Howard G. Smith remind investors that April 7, 2026, is the deadline to file a lead plaintiff motion in a class action on behalf of investors who purchased Inovio Pharmaceuticals (NASDAQ: INO) securities between October 10, 2023, and December 26, 2025, highlighting investor concerns over the company's future prospects.
- Financial Impact: On August 8, 2024, Inovio reported its Q2 financial results, revealing a delay in submitting the Biologics License Application (BLA) to mid-2025 due to manufacturing issues, which caused its stock to drop 3.1% to $8.44 per share the following day, indicating market skepticism regarding the company's management capabilities.
- FDA Review Dynamics: On December 29, 2025, Inovio disclosed that the FDA accepted its INO-3107 BLA on a standard review timeline instead of an accelerated one, leading to a 24.45% drop in stock price to $1.73 per share, further exacerbating investor losses and reflecting the company's challenges in regulatory compliance.
- False Statement Allegations: The lawsuit alleges that Inovio failed to disclose manufacturing deficiencies and their impact on the INO-3107 application throughout the class period, leading to investor misconceptions about the company's prospects, which underscores significant shortcomings in the company's transparency and integrity.
See More
Inovio Pharmaceuticals Securities Fraud Lawsuit Reminder
- Lawsuit Deadline: The Law Offices of Howard G. Smith remind investors that April 7, 2026, is the deadline to file a lead plaintiff motion for those who purchased Inovio securities between October 10, 2023, and December 26, 2025, highlighting the urgency and significance of the case.
- Financial Impact: On August 8, 2024, Inovio released its Q2 financial results, indicating a delay in submitting the Biologics License Application due to manufacturing issues, which caused the stock price to drop 3.1% to $8.44 per share the following day, directly affecting investor confidence.
- FDA Review Update: On December 29, 2025, Inovio disclosed that the FDA accepted its INO-3107 BLA but on a standard review timeline rather than the anticipated accelerated review, leading to a 24.45% stock price decline to $1.73 per share, further exacerbating investor losses.
- False Statements Allegations: The lawsuit alleges that throughout the class period, Inovio failed to disclose deficiencies in the manufacturing of its CELLECTRA device, resulting in misleading positive statements about the regulatory and commercial prospects of INO-3107, severely misguiding investor judgment.
See More
Inovio Pharmaceuticals Investors Class Action Notice
- Class Action Initiated: The Portnoy Law Firm advises Inovio Pharmaceuticals investors of a class action for those who purchased securities between October 10, 2023, and December 26, 2025, with a deadline of April 7, 2026, to file a lead plaintiff motion to protect their legal rights.
- False Statements Allegations: The lawsuit claims that during the class period, Inovio's management made false and misleading statements, failing to disclose deficiencies in the manufacturing of its CELLECTRA device, which decreased the likelihood of submitting the INO-3107 Biologics License Application (BLA) to the FDA.
- FDA Review Outcome: On December 29, 2025, the FDA accepted Inovio's INO-3107 BLA but indicated that the company did not provide sufficient information to justify eligibility for accelerated approval, leading to overstated regulatory and commercial prospects for the product.
- Significant Stock Drop: Following the FDA announcement, Inovio's stock price fell by $0.56, or 24.45%, closing at $1.73 per share, reflecting a pessimistic market sentiment regarding the company's future, resulting in investor losses.
See More
Inovio Pharmaceuticals Shareholder Class Action Notice
- Class Action Notice: The Gross Law Firm has issued a notice encouraging shareholders who purchased Inovio Pharmaceuticals (NASDAQ: INO) shares between October 10, 2023, and December 26, 2025, to contact them for potential lead plaintiff appointment to partake in recovery.
- Allegations Overview: The complaint alleges that during the class period, Inovio made materially false and misleading statements, failing to disclose deficiencies in the manufacturing of its CELLECTRA device, which overstated the regulatory prospects of its lead product candidate, INO-3107.
- Regulatory Approval Concerns: Due to manufacturing issues, Inovio is unlikely to submit its BLA for INO-3107 to the FDA by the second half of 2024, which could adversely affect the company's future revenue and market performance.
- Shareholder Registration Deadline: Shareholders must register for the class action by April 7, 2026, to avoid losing their claim opportunities, with the Gross Law Firm offering portfolio monitoring services to keep investors updated on the case's progress.
See More
Inovio Pharmaceuticals Shareholder Class Action Notice
- Class Action Notice: The Gross Law Firm has issued a notice to shareholders of Inovio Pharmaceuticals, encouraging those who purchased INO shares between October 10, 2023, and December 26, 2025, to contact the firm regarding potential lead plaintiff appointment for recovery participation.
- Allegations: The complaint alleges that during the class period, Inovio made materially false and misleading statements, failing to disclose deficiencies in the manufacturing of its CELLECTRA device, which may delay the submission of its lead product candidate INO-3107 to the FDA until the second half of 2024.
- Regulatory Uncertainty: Inovio lacked sufficient information to justify INO-3107's eligibility for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects, which could result in significant losses for investors.
- Participation Deadline: The deadline for shareholders to register for the class action is April 7, 2026, and those who do not register may miss the opportunity for claims, thus it is advised to act promptly to protect their rights.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit Notification
- Class Action Initiation: Levi & Korsinsky LLP has notified investors in Inovio Pharmaceuticals of a class action lawsuit due to alleged securities fraud, covering the period from October 10, 2023, to December 26, 2025, aimed at recovering losses for affected investors.
- Allegation Details: The complaint alleges that defendants concealed deficiencies in the manufacturing of Inovio's CELLECTRA device, which may delay the submission of its lead product candidate, INO-3107, to the FDA until the second half of 2024, and lacked sufficient information to justify its eligibility for accelerated approval, impacting its market prospects.
- Investor Rights: Affected investors have until April 7, 2026, to request to be appointed as lead plaintiff, with participation in any recovery requiring no out-of-pocket costs, ensuring investor rights are protected.
- Legal Team Strength: Levi & Korsinsky boasts 20 years of experience in securities litigation, having secured hundreds of millions for shareholders, and has been ranked among the top securities litigation firms in the U.S. for seven consecutive years, showcasing its expertise in complex securities cases.
See More
